Crunching Numbers: A Critical Look at Annual Reports by Caron, Stephanie
Western Kentucky University
TopSCHOLAR®
Honors College Capstone Experience/Thesis
Projects Honors College at WKU
Spring 2007
Crunching Numbers: A Critical Look at Annual
Reports
Stephanie Caron
Follow this and additional works at: http://digitalcommons.wku.edu/stu_hon_theses
Part of the Accounting Commons
This Thesis is brought to you for free and open access by TopSCHOLAR®. It has been accepted for inclusion in Honors College Capstone Experience/
Thesis Projects by an authorized administrator of TopSCHOLAR®. For more information, please contact connie.foster@wku.edu.
Recommended Citation
Caron, Stephanie, "Crunching Numbers: A Critical Look at Annual Reports" (2007). Honors College Capstone Experience/Thesis
Projects. Paper 125.
http://digitalcommons.wku.edu/stu_hon_theses/125
1Background
“I mean, the company had a lot of strong cash flows when it went into 
bankruptcy,” Enron CEO Ken Lay stated.  Unfortunately for the company – and the 
whole country – Kenneth Lay did not completely understand the information that was 
presented on Enron’s financial statements.  He was not alone in his incompetence.  Much 
of the American business population is lacking in its financial-analysis skills, skills that
should be put into use before making any investment.  One way to learn how to analyze
the financial reports is to examine the statements of two different companies.  But to truly 
understand these comparisons, one should begin with a brief background of financial 
statements themselves.  
The story of the financial statement’s birth begins around 1929 with the crash of 
the stock market.  The havoc that reigned in that era led many Americans to call for the 
government to regulate and supervise the financial arena.  In response, the federal 
government passed the Securities Act of 1933.  This act had two basic objectives: (1) to 
require that investors receive significant (“material”) information concerning securities 
offered for public sale, and (2) to prohibit deceit, misrepresentation, and other forms of 
fraud in the sale of securities.  To further extend federal regulation on securities, the 
Securities Act of 1934 established the Securities and Exchange Commission, known to 
businesses and business students alike as the SEC.  Following the guidelines set out for it 
in the 1934 Securities and Exchange Act, the SEC began dictating accounting practices 
2and standards (Kieso 6).  However, the SEC’s guidance focused primarily on publicly 
traded securities and the markets in which they are traded.  It was through the American 
Institute of Certified Public Accountants (AICPA) and the Financial Accounting 
Standards Board (FASB) that the accounting guidelines began an even greater evolution.
The AICPA, which has been around much longer than the SEC, is a professional 
organization composed of Certified Public Accountants.  It was through the urging of the 
SEC that the AICPA began its contribution to the Generally Accepted Accounting 
Principles (GAAP).  In 1939 the SEC convinced the AICPA to form a Committee on 
Accounting Procedure (CAP), and from 1939-1959 this committee issued fifty-one
Accounting Research Bulletins.  These bulletins covered a variety of accounting 
problems, but these were not enough to properly establish true accounting principles 
(Kieso 7).  Thus, there was the inception of the Accounting Principles Board (APB).
The APB, also created by the AICPA, was formed “(1) to advance the written 
expressions of accounting principles, (2) to determine appropriate practices, and (3) to 
narrow the areas of difference and inconsistency in practice” (Kieso 8).  With its eighteen 
to twenty-one members, the APB sought to release APB Opinions to resolve problems as 
they became evident.  Eventually, the APB came under fire for a lack of prompt response 
to problems, and was dissolved in 1973, having released a total of thirty-one opinions 
(Kieso 8).  At this time the AICPA formed yet another committee to evaluate the 
situation.  This committee, headed by Francis Wheat, determined that the APB should be 
replaced by three separate entities: the Financial Accounting Foundation (FAF), the 
Financial Accounting Standards Board (FASB), and the Financial Accounting Standards 
3Advisory Council (FASAC) (Kieso 8).  While each has its designated duties, it’s the 
FASB that is of primary importance.
The premise for the foundation of the FASB was to improve upon the format of 
the APB.  This time the committee would have only seven members rather than a 
minimum of eighteen.  These members were to be appointed by the FAF and would serve 
for renewable five-year terms, occupying paid, full-time positions, unlike members of the 
APB.  Furthermore, members of FASB were not required to be either CPAs or members 
of AICPA, and answered solely to the FAF rather than the AICPA.  FASB members also 
severed all links to their previous companies (Kieso 8).  Such regulations have allowed 
the FASB to survive for more than thirty years.
In its lifetime the FASB has had a profound effect on the accounting profession.  
Thanks to this organization, the Generally Accepted Accounting Principles (GAAP) are 
constantly reviewed and amended in a timely fashion, something that was lacking under
the AICPA’s previous committees.  As society evolves to face new challenges, so do 
these principles.  Accordingly, the FASB has proven to be a vital guide for the 
accounting world.
While GAAP is considered the main source of rules and regulations, it is not the 
only major influence on the accounting profession.  In light of recent accounting scandals 
involving such corporations as Enron and WorldCom, Congress approved legislation that
attempts to prevent future fraud.  This legislation – known to the world as the Sarbanes-
Oxley Act (or SOX, for short) – goes to great lengths to increase the validity of financial 
statements.  With the enacting of SOX came the creation of yet another committee: The 
Public Company Accounting Oversight Board (PCAOB).  It was formed to ensure that 
4regulations of SOX were upheld by both companies and accountants (Tracy 136).  Given
the length of restrictions imposed by SOX, this is and will likely continue to be a 
daunting task.
Included among the restrictions of SOX is an effort to hold both Chief Executive 
Officers and Chief Financial Officers responsible for a company’s financial reports.  Both 
officers are required to sign off on the documents, so lack of knowledge about the 
financial affairs of the company is no longer a valid defense.  Other major provisions 
covered in SOX include the following:
 Prohibition of personal loans to any Executive Officer and Director
 Quicker reporting of inside trading
 Ban on insider trades during pension-fund blackout periods 
 Disclosure of CEO and CFO compensation and profits 
 Full disclosure on a number of segments
 Longer jail sentences for executives who knowingly falsify financial 
statements
 Penalties, both civil and criminal, for a violation of a security law
 Disallowing firms that offer audit services to a company from also 
providing other services to that company, such as advising
 Requiring publicly traded companies to supply separate annual audit 
reports of the existence and reliability of internal controls in regard to 
financial reporting
(Sarbanes-Oxley Act Wikipedia)
Complying with all these regulations can prove costly and time-consuming for a 
business, but for the present, companies have no other option.
While this is the case, there is one constant to be considered: what must be 
reported by the company.  In each annual report, a company has to provide the public 
with four different reports: the income statement, the balance sheet, the statement of 
owners’ equity, and the statement of cash flows.  Without knowledge of these reports, the 
numbers presented mean absolutely nothing.  
5To most investors, the important numbers are all found on the income statement.  
As the name indicates, this statement presents the income information.  Here one will 
find a company’s revenues and expenses.  The income statement also houses the 
earnings-per-share figures, which are indicative of how much earnings shareholders 
would receive if a company were to distribute all of its net earnings, something that rarely 
happens as this income is usually reinvested into the company.
The income statement begins with revenues for the period and progresses with 
deductions for expenses that were incurred to earn this income.  On any income 
statement, the first number will always be sales, or gross revenue, since expenses have 
yet to be deducted.  Following this, a deduction will be made for adjustments (such as 
discounts, returns, and allowances) to sales.  This total is the company’s net revenue.  
From net revenue, the cost of goods sold, or cost of sales, will be deducted to come to a 
figure known as the company’s gross profit.  At this time, any operating expenses 
(including depreciation, administrative costs, and research and development) that have 
occurred will be subtracted to show the income from operations (income before taxes and 
interest).  The next step is to account for gains, losses, interest income, and interest 
expense to determine the company’s income before taxes.  Finally, income-tax expense is 
deducted to reach the company’s “bottom line,” the net income or loss for the period 
(“Beginner’s Guide to Financial Statements” U.S. Securities and Exchange Commission).
Statement number two, the balance sheet, is often defined as “a snapshot of a 
company’s assets, liabilities and shareholders’ equity at the end of the reporting period” 
(“Beginner’s Guide to Financial Statements” U.S. Securities and Exchange Commission).  
The amount of the company’s assets is equivalent to liabilities plus equity.  Under assets, 
6one can find the property of the company (ex. buildings, land, equipment, cash, patents, 
etc.).  These assets are divided into current (assets that are expected to be converted into 
cash within the next year) and noncurrent (assets that will not be converted within the 
next year, including any fixed assets, i.e., goods not available for sale).  Within the 
current classification, the items are listed in order of liquidity (how quickly the item 
could be converted into cash, with the most liquid being listed first).  Liabilities catalog
what the company owes to others (ex. loans, rent, payroll, taxes due, etc.).  Items in this 
category are subdivided into current (within the year) or long-term (due in more than one 
year).  The stockholder’s equity section can also be expressed as the owners’ claims to 
assets.  “It’s the income that would be left if a company sold all of its assets and paid off 
all of its liabilities” (“Beginners’ Guide to Financial Statements” U.S. Securities and
Exchange Commission).  This amount belongs to the shareholders, who are essentially 
the owners of the company.  It includes the income invested by the shareholders, 
plus/minus the earnings/losses of the company since its founding (the retained earnings) 
minus any dividend distributions.  
Often the stockholder’s equity section can be viewed in greater detail on its own 
statement, the statement of owners’ equity.  Here, changes in individual equity balance 
during the year are explained.  This section typically shows a snapshot of comprehensive 
income plus/minus receipts from the issuance of new stock, repurchase of outstanding 
shares, stock options exercised, and settlements of call spreads.
The final report enclosed in the annual report is the statement of cash flows, an 
account of a company’s cash in- and outflows, indicating where the company’s cash 
came from and went to.  The cash flow is divided up into three categories based on its 
7purpose: operating, investing, and financing.  The operating activities section includes 
cash flow from the net income or loss.  It begins with the net income and then adds back 
any non-cash operating expenses (i.e. depreciation expense).  To get cash used/provided 
by operating activities, adjustments are made for changes in the current assets and 
liabilities accounts.  Under investing, the cash flow from investments is listed.  This 
includes the acquisition or sale of property, plant, equipment or securities.  Finally, one 
will come to the financing section, which typically includes cash flow from issuing stocks 
and bonds as well as any debt retired or distributions made to the owners (“Beginner’s 
Guide to Financial Statements,” U.S. Securities and Exchange Commission).
8Two Pharmaceutical Companies
Sepracor
Sepracor, a pharmaceutical company founded in 1984, is based in Marlborough, 
Massachusetts.  Over the years, it has developed such drugs as Clarinex and Allegra, both 
of which have been licensed to other pharmaceutical companies.  Currently, Sepracor 
markets three products on its own: Xopenex, Xopenex HFA, and Lunesta.  When it 
comes to accounting matters, Sepracor relies on Computershare in Providence, Rhode 
Island, to take care of stock issuances.  PricewaterhouseCoopers, LLC in Boston makes 
sure that Sepracor’s financial statements are all in line.
For the year ending December 31, 2005, Sepracor initially appeared to be a good 
investment.  In his letter to the shareholders, Timothy Barberick, Sepracor’s president, 
attempted to sell this idea as well.  Barberick noted that for the first time in years, 
Sepracor was headed toward profitability.  Thanks to Xopenex and Lunesta sales, the 
company earned upward of $700 million.  Today, Sepracor has another drug up for 
approval with the FDA, a drug which could potentially provide the company with 
additional revenues.  Unfortunately, when it is a matter of investing earnings, words 
cannot be taken at face value.  One must delve into Sepracor’s financial statements to see 
how true Barberick’s words were.  A good place to begin investigating is within 
Sepracor’s income statement.  
9In the 2005 Annual Report, Sepracor provided income statement information 
dating back to 2001, but the data for years 2004 and 2005 are of primary importance here.  
At first glance, one may notice Sepracor’s sales growth from 2004 to 2005:
(769,685,000 – 319,781,000) = 140.69%
319,781,000
In one year’s time, Sepracor’s sales revenue grew nearly 141 percent, which can likely be 
accredited to the “commercial introduction of Lunesta in April 2005 and a significant 
increase in Xopenex Inhalation Solution revenue” (21 Sepracor: 2005 Annual Report).  
Sepracor’s change in net income is also worth noting:
(4,971,000 - (295,658,000)) = 101.68%
|-295,658,000|
Net income in 2005 more than doubled from 2004.  
Yet it is imperative to dig deeper.  At this time, a common-size analysis is in 
order.  Common-size analysis measures the various accounts as a percentage of sales.
2005 2004
Cost of Sales (8.80%) (11.10%)
Gross Profit 91.20% 88.90%
Selling, General, and Administrative 
Expenses (81.30%) (121.30%)
Interest Expense (3.03%) (7.40%)
Income Tax Expense (0.02%) 0.00%
Earning from Continuing Operations 0.65% (92.50%)
Net Income 0.65% (92.50%)
From this illustration, it is evident that Sepracor was able to better manage income in 
nearly every category on the income statement.  For the first time in all years listed, 
Sepracor posted a positive net income.  In the overall picture, expenses were a decreasing 
part of the finances, while net income was exceptionally higher (from a negative 92.5 
10
percent of sales to a positive .65 percent) due to a vast increase in sales.  In reference to 
this turnaround for Sepracor, President Barberick observed:
The year 2005 was a tremendous year for Sepracor and our stakeholders and 
marks a significant inflection point in the history of the company.  In 2005, we 
turned the corner in our advance to profitability…a 116 percent increase over 
2004. (Sepracor 1)
Investors can only hope that Sepracor continues down its current path.  For insight into its 
staying power, one should next consult Sepracor’s balance sheet.
Following the same format as the income statement, another common-size 
analysis is in order, but to find the relation of an account to Sepracor’s total assets.
% of Total Assets 2005
Current Assets 82.10%
Fixed Assets 5.70%
Investments 10.80%
Intangible Assets 1.40%
Other Assets 0.01%
Current Liabilities 21.80%
Total Liabilities 113%
Total Equity -13%
One can see that Sepracor is holding more liabilities than assets, which could prove 
detrimental.  However, this fact alone is not sufficient to deter an investor’s interest.  
Instead, one should then look at the specifics about assets to determine the validity of the 
aforementioned conclusion.
If a company’s assets increase from one year to the next, it is considered to be 
growing.  This can be measured via the asset-growth calculation using the current and 
previous year total assets figures:
1,274,497,000 – 1,039,118,000 = 22.65%
1,039,118,000
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Because of its expansion in the drug market, there was a significant increase in short-term 
investments, accounts receivable, inventories, other current assets, long-term 
investments, and property and equipment, leading Sepracor’s total assets to increase more 
than 22 percent in 2005, a good sign for the future of the business.  Growth alone cannot 
sustain a business, though.
Sepracor’s ability to pay current liabilities is crucial to its survival.  Working 
capital helps to calculate Sepracor’s liquidity.
2005 2004
Current Assets 1,046,545,000 839,930,000
Current Liabilities (277,906,000) (204,110,000)
Working Capital 768,639,000 635,820,000
Currently, Sepracor has more than enough assets to cover its liabilities.  Liquidity of the 
company even increased from 2004 to 2005 by 20.89 percent:
768,639,000 - 635,820,000 = 20.89%
635,820,000
The balance sheet suggests that such a change can be attributed to considerable increases 
within short-term investments, accounts receivable, and inventory.  At the bottom of the 
balance sheet is another important figure: Sepracor’s retained-earnings amount.  For 
details concerning this number, one can turn to the Statement of Shareholders’ Equity 
(Deficit) and Comprehensive Income.
For the year 2005, Sepracor’s capital stock amounts changed due to the issuance 
of 3,045 shares to employees under stock plans.  Other than that, few changes occurred 
within Sepracor’s stockholders’ equity to result in the following overall change:
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2005 2004
Retained Earnings, Beginning (1,625,486,000) (1,329,828,000)
Dividends 0 0 
Net Income 4,971,000 (295,658,000)
Retained Earnings, End (1,620,515,000) (1,625,486,000)
In this area, Sepracor does not bode well.  The amount in retained-earnings is increasing, 
but is still a rather large negative.
With Sepracor’s fourth and final statement, one can analyze the company’s cash-
flow management.  The report indicates that cash was spent in the following manners:
2005 2004
Operating (22,617,000) (183,329,000)
Investing (400,908,000) (279,730,000)
Financing 165,591,000 193,060,000 
Effect of Exchange Rate 173,000 102,000 
Change in Cash (257,761,000) (269,897,000)
The 2005 change in cash is also reflected upon the balance sheet:
Cash, 2005 178,144,000 
Less: Cash, 2004 435,905,000 
Change in Cash (257,761,000)
As one can see, Sepracor’s cash balance decreased overall by $257,761,000.  Typically, it 
is desirable for income to come from operating activities rather than investments or debts.  
However, the net income figure was largely comprised of funds from other sources:
(22,617,000) - 4,971,000 = (27,588,000)
Yet one must consider that Sepracor obtained much of its income through product sales, 
which aren’t reflected in this figure if a cash payment was received.  Royalty payments 
also inflated the net income figure, but are not found in the operating section of the cash-
flow statement.
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Analysis of the statement of cash flows shows that Sepracor expended 
$1,293,075,000 on short- and long-term investments.  Call-spread options provided the 
company with $123,798,000.  Investments in non-affiliates and loss on disposal of 
property and equipment both decreased the cash balance, while a gain of the sale of 
equity investments increased cash.
While these four reports provide investors with useful information, some of the 
most valuable facts can be found within the notes and supporting schedules of the annual 
report.  These sections include footnotes with crucial information about the methods 
employed in running the company.
It is in the subsequent notes that one can find specifically what investments 
Sepracor is holding.  Here, one will find that Sepracor is accounting for its investment in 
BioSphere Medical, Inc. under the equity method, meaning it owns twenty to fifty 
percent of Biosphere.  As part of the equity method, Sepracor must recognize a 
percentage of BioSphere’s income as part of its own.  For 2005, ($665,000) was 
recognized.  The notes also name Sepracor’s marketable equity securities (investments of 
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less than twenty percent of another company) as Point Therapeutics and ACADIA 
Pharmaceuticals, as well as Vicuron, which was sold during 2005.  Overall, the value of 
its marketable securities changed by $7,143,000, which was amortized on Sepracor’s 
financial statements.
The notes also define important terms found within the financial reports.  “Cash 
equivalents,” found on the balance sheet, are described as “highly liquid, temporary cash 
investments having original maturity dates of three months or less” (50).  The valuation 
of inventory is identified as first-in, first-out, which results in a higher net income, but 
also a higher tax expense.  One will also find that Sepracor employs straight-line 
depreciation for its property and equipment.  Sepracor’s notes reveal that it relies upon 
three customers for sixty-nine percent of its total business.  For this reason, Sepracor 
must closely manage its receivables.
The notes also assess credit risk.  This risk may come from cash and cash 
equivalents, short- and long-term investments, and trade accounts receivable.  According 
to the report, there are no significant off-balance-sheet concentrations of credit risk.  To 
avoid potential credit risk, Sepracor places any “risky” accounts with high-credit-quality 
financial institutions.  When examining Sepracor’s receivables accounts, though, one will 
find that it is becoming slightly less conservative with its allowance for uncollectible 
accounts.  For the year 2005:
3,103,000 = 2.20%
(140,465,000 + 3,103,000) 
Of all receivables, Sepracor believed only 2.2 percent would not be collected.  For the 
year 2004:
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1,786,000 = 2.57%
 (68,914,000 + 1,786,000) 
Sepracor believed a slightly larger 2.57 percent would not be collectible.  Since Sepracor 
estimated a smaller percentage in 2005, more assets were available to apply toward the 
bottom line, though this addition is minimal.  The validity of Sepracor’s assumption can 
be tested in a variety of manners.  
One such test involves measuring the average number of days it took Sepracor to 
collect on accounts:
140,465,000 = 66.61 Days
769,685,000/365
This number was down from the previous year:
68,914,000 = 78.66 Days
319,781,000/365
Measuring the turnover of accounts receivable is also indicative of how well Sepracor 
collected payments.  For 2005 the turnover rate was:
769,685,000 = 7.35 Times
(140,465,000+68,914,000)/2
In 2004, Sepracor saw a turnover rate of
319,781,000 = 5.35 Times
(68,914,000+50,591,000)/2
Examination of this information suggests that 2005 was a more efficient year for 
Sepracor as it was more successful in collecting accounts receivable and receiving this 
money at a quicker rate.
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Inventory acts as an inflation of net assets.  While Sepracor may have a large 
number of dollars in inventory, it is important to consider how liquid this figure is.  Upon 
investigating, one can find an average of how many days a good spent in inventory.  For 
2005:
38,951,000 = 213.21 Days
66,682,000/365
While in 2004:
13,086,000 = 138.64 Days
34,451,000/365
It is not a good indication when Sepracor is holding inventory for nearly a hundred days 
longer in 2005 than 2004.  When goods are held for 213 days, it is likely that this account 
is not a very liquid one.  
The inventory turnover ratio also measures how quickly the goods were 
completely sold to provide a picture of product demand.  The 2005 ratio:
34,451,000 = 1.33 Times
(13,086,000 + 38,781,000)/2
It is apparent that Sepracor did not quickly sell its goods during 2005.  If for some reason 
the drugs that Sepracor sells should become obsolete, the company’s situation would be 
dire.  According to the notes, approximately $17 million of inventory is in the finished 
goods state, so this would all have to be written off as a loss.  Not only would this hurt 
the growing company, the market implications would be horrific.  
Specific information about Sepracor’s debt can also be found within the pages of 
the subsequent notes.  As of December 31, 2005, the balance of borrowings stood at 
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$1,160,820,000.  This debt is divided amongst several zero-percent notes and a five-
percent debenture.  Because of the arrangement of debt, there were no principal payments 
for 2005.  However, within the next five years, Sepracor has a large amount of debt 
coming due.  Sepracor is also committed to a debt for leases for office facilities, a vacated 
office, laboratory and production facilities, and regional offices.  Under these leases, it is 
required to pay an allocated amount of taxes and operating costs in addition to rent.
This section of the annual report also defines benefits for the employees.  
Sepracor has a defined contribution plan, meaning employees are only guaranteed money 
that they put in as well as any monies that the company contributes to match their 
investments.  In 2005, Sepracor allocated $2,286,000 toward employee pension expense.  
The company personnel are also granted stock options.  The company gives options to 
purchase stock as of the day the options are granted.  However, the total number of 
options is vested over a period of time so that employees will have the incentive to stick 
around to use the options.  A typical employee will have twenty to forty thousand 
options, with executives and board members getting more than that.  In 2005, employees 
used $6,725,000 worth of said stock options.  This was equivalent to 3,400,000 stocks at 
a price of $33.94 a share.  At year’s end, the value of outstanding options was 
$115,396,000.
Income taxes are also addressed in this section.  In 2005, Sepracor paid $151,000 
in income tax.  However, in 2004, Sepracor paid $0 as it had a taxable loss, thus 
generating a tax credit.  This tax credit was also carried forward to 2005, making the 
effective tax rate only 2.9 percent.
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Another important issue covered is legality.  Upon publication of the annual 
report, Sepracor’s current and former officers and the current director were all defendants 
in a case concerning possible deception in getting FDA approval of tecastemizole.  The 
case was filed by the people who purchased common stock and/or debt securities 
between May 17, 1999, and March 6, 2002.  However, Sepracor and its attorneys are 
unsure how the matter will turn out, but state that “Any conclusion of these matters in a 
manner adverse to us would have a material adverse effect on our financial position and 
results of operations” (60).  Sepracor has also filed suit against Breath Limited and Dey, 
L.P. for patent infringement of XOPENEX.
The company also notes that after the close of the 2005 financial statements, 
Sepracor purchased 813,393 shares of ACADIA at a premium of $12.29 a share.  This 
investment completed an agreement between the two companies, making Sepracor a large 
owner of ACADIA’s stocks.  Thus, the performance of ACADIA could have a great 
impact upon Sepracor’s future finances.  
Beyond the subsequent notes, one can find supplemental disclosures.  These 
disclosures include the management report and the auditors’ report.  In the management 
report, Timothy Barberick, Sepracor’s CEO, and Robert Scumaci, the executive vice 
president of finance and administration, are identified as the individuals responsible for 
the validity of the annual report.  The two subscribe to the Private Securities Litigation 
Reform Act of 1995 to ensure that they properly complete the financial statements.
Within the Report of the Independent Auditors, Pricewaterhouse Cooper 
expresses its opinion on the accuracy of Sepracor’s annual report.  Pricewaterhouse 
follows the guidelines set-up by Sarbanes-Oxley and the Public Company Accounting 
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Oversight Board.  Upon review, the auditors issued an unqualified opinion of Sepracor’s 
statements, meaning the report followed GAAP guidelines.  Pricewaterhouse stated:
“…in our opinion, management’s assessment included in Management’s Report on 
Internal Control Over Financial Reporting…based on criteria established in Internal 
Control-Integrated Framework…is fairly stated” (45).  However, the auditors added the 
disclaimer:
Because of its inherent limitations, internal control over financial reporting may 
not prevent or detect misstatements.  Also, projections of any evolution of 
effectiveness to future periods are subject to the risk that controls may become 
inadequate because of changes in conditions or that the degree of compliance with 
the policies or procedures may detect. (45)
This was indeed the case when in 2006 the SEC began investigating Sepracor’s 
accounting for stock options.  This investigation led to a restatement of income for 2006 
as well as prior years.  These figures have not been used in any calculations shown.
Profitability ratios help to measure the corporation’s success in operations.  The 
profit-margin calculation measures how much of each sale goes toward the earnings.  
Sepracor’s 2005 profit-margin:
4,971,000 = 0.65%
769,685,000
This may seem small, but is a vast improvement from Sepracor’s 2004 figures:
-295,658,000 = -  92.46%
319,781,000
Another measure to indicate how well Sepracor managed to turn its assets into profit lies 
within the return on assets figure:
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4,971,000 = 0.43%
(1,274,497,000 + 1,039,118,000)/2
According to this figure, Sepracor’s assets appear poorly managed.  If borrowed monies 
are taken out of this figure, one can measure Sepracor’s return on equity in 2005:
4,971,000 = -2.00%
(-165,489,000+-331,115,000)/2
This figure does not improve things at all for Sepracor’s outlook.  Past occurrences must 
be taken into consideration, though.  For the past few years, Sepracor has suffered a net 
loss, which resulted in a large impact on equity.  Thus, equity has been a negative 
number, leading to a negative return on equity.  Sepracor is taking steps toward a more 
positive future, which is reflected in the fact that 2005 was the first year it was actually 
profitable thanks to Lunesta and XOPENEX.  This profit led to an earnings per share of 
$.05, up from $(3.21) in 2004.
The next step is to gauge Sepracor’s ability to pay its impending debt via liquidity 
ratios.  The current ratio measures current assets against current liabilities.  This figure 
for Sepracor in the year 2005 was as follows:
1,046,545,000 = 3.77 :1
277,906,000
Versus 2004:
839,930,000 = 4.12 :1
204,110,000
According to these calculations, Sepracor does currently have the funds available to pay 
its upcoming debt three times over, but the coverage has decreased for 2004 to 2005.  
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However, the current ratio does not account for the fact that some of the current assets are 
not as liquid as others.  Thus, one can perform a quick ratio to determine a more accurate 
ability to pay liabilities by only considering cash, marketable securities, and net 
receivables:  In 2005, this came to
178,144,000 + 666,615,000 + 140,465,000 = 3.55 :1
277,906,000
Whereas 2004 saw this number at
435,905,000 + 303,303,000 + 68,914,000 = 3.96 :1
204,110,000
Again, Sepracor’s liquidity weakened as the current liabilities grew more quickly than 
did its current assets.
The final set of ratios measure the company’s solvency.  These ratios are 
important for lenders to consider.  If Sepracor has a small debt-to-total-assets ratio, it is 
more likely to receive monies because it likely has the funds to cover its debt.  In 2005, 
Sepracor’s debt to total assets ratio came in at
1,439,986,000 = 112.98%
1,274,497,000
And in 2004:
1,370,233,000 = 131.87%
1,039,118,000
As of 2005, Sepracor is able to cover more of its debt, but does not have the ability to pay 
off all of its liabilities.  While debt did increase due to increased expenses and payables 
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accounts, the company’s assets grew more quickly due to short-term investments, 
accounts receivables, inventories, and long-term investments.
The times-interest-earned ratio measures the amount paid in interest compared to 
a company’s income.  This figure helps to determine if too much is being spent to service 
debt.  This ratio for Sepracor for 2005 came to
4,971,000 + 23,368,000 + 151,000 = 1.22 times
23,368,000
Whereas this figure for 2004 came to
-295,658,000 + 23,646,000 + 0 = -11.50 times
23,646,000
When considering these figures it is important to remember that Sepracor performed so 
poorly that it received a tax credit from the government, which skews the 2004 figure.
An important figure to many investors involves the book value of a share.  The 
value of a share at the end of 2005 was
-165,489,000 = -$1.59
104,093,000
In comparison to 2004:
-331,115,000 = -$3.20
103,376,000
The value of the share has increased in the past year.  With the belief that Sepracor will
continue to grow, investors may be willing to pay a premium to hold these shares.
There is one final way to predict the future of a company.  Financial distress 
prediction models can help investors by measuring the probability that a company will go 
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bankrupt.  Altman’s “Z-score” Model and Hopwood, McKeown, and Mutchler’s Logistic 
Regression Model are both viewed as being very accurate on the matter.  Following 
Altman’s method, Sepracor scored as follows:
X1= 768,639,000/1,274,497,000 = 0.603 X 1.2 = 0.724
X2= -1,620,515,000/1,274,497,000 = -1.271 X 1.4 = -1.780
X3= [5,122,000+27,462,000]/1,274,497,000 = 0.026 X 3.3 = 0.084
X4= [51.6*104,093]/1,439,986,000 = 0.004 X .6 = 0.002
X5= 769,685,000/1,274,497,000 = 0.604 X 1.0 = 0.604
Z = -0.366
This model defines a company as safe if it scores higher than a 3.0.  A score from 1.8 to 
3.0 is viewed as gray.  Less than a 1.8 means the company is an unsafe investment, which 
is the category Sepracor’s score falls in.  Using Hopwood, McKeown, and Mutchler’s
Logistic Regression method, which measures a company’s probability of bankruptcy, the 
company scores poorly:
X1= 4,971,000/1,274,497,000 = 0.004 X -32.36 = -0.126
X2= 1,046,545,000/769,685,000 = 1.360 X .55 = 0.748
X3= 1,046,545,000/277,906,000 = 3.766 X -.07 = -0.264
X4= 1,046,545,000/1,274,497,000 = 0.821 X 1.42 = 1.166
X5= 178,144,000/1,274,497,000 = 0.140 X -7.45 = -1.041
X6= 1,162,080,000/1,274,497,000 = 0.912 X 2.7 = 2.462
2.145
Probability = 1 = 89.46%
(1 + 2.71 ^-2.145)
According to the first model, Sepracor is not truly classifiable.  However, the second 
method predicts that there is an 89.46 percent chance that it will fail, making Sepracor a 
very risky investment. For further details regarding these models, see Appendix A.  Upon 
completion of these figures, the investor is ready to compare Sepracor to others in its 
market.
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King Pharmaceutical
King Pharmaceuticals began operations during 1994 in Bristol, Tennessee.  It 
started off by manufacturing pharmaceutical products for other corporations such as 
SmithKline Beecham and Novartis.  In the years since then, the company has shifted its 
focus and now concerns itself with acquiring pharmaceutical products that are late in the 
development process, as well as developing drugs of its own.  Currently, the key products 
King markets include Altace, Skelaxin, Thrombin-JMI, Sonata, Levoxyl, and Meridian 
Auto injector products.  As for its finances, King relies on American Stock Transfer and 
Trust Company in New York City to issue its stock and PriceWaterhouseCooper in 
Raleigh, North Carolina, to ensure the accuracy of its financial statements.
At the end of 2005, King’s CEO, Brian Markison, sang the praises of his 
company, calling it a year of “significant accomplishments...revenues rose to 
approximately $1.8 billion, and cash flow from operations increased to $520 million, 
both record highs” (King Pharmaceuticals 2005 Annual Report 2).  Markison went on to 
note that during 2005, King managed to overcome many challenges en route to a 
successful business plan, focusing on the therapeutic areas of cardiovascular/metabolics, 
neuroscience, and hospital/acute care.  But just how successful has King been?
Income during the year 2005 rose
1,694,753,000 - 1,225,890,000 = 38.25%
1,225,890,000
Although the income change was not nearly as dramatic as Sepracor’s 140.25 percent, it 
did not have quite as much room to grow as Sepracor did either.  Compared to the 101.68 
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percent increase in net income, King also overcame a negative net income in 2004 to post 
a rise of 
117,833,000 - (160,288,000) = 173.51%
|-160,288,000|
An overall comparison of the income statement shows the following:
Sepracor King
2005 2004 2005 2004
Cost of Sales -8.80% -11.10% -19.06% -28.79%
Gross Profit 91.20% 88.90% 85.55% 77.61%
Selling, General, and Administrative 
Expenses -81.30% -121.30% -24.16% -33.43%
Interest Expense -3.03% -7.40% 0.70% -1.03%
Income Tax Expense -0.02% 0.00% -3.63% -0.60%
Earning from Continuing Operations 0.65% -92.50% 6.88% -4.13%
Net Income 0.65% -92.50% 6.95% -13.08%
While the income statement of King almost clearly gives the impression that it is better 
off than Sepracor, this is not basis enough to make a decision.  Analysis of the balance 
sheet will provide more insight into the matter.
When comparing balance sheet figures to total assets, one can observe that
Sepracor relies more on current assets and investments than does King, and it also has a 
much larger percentage of liabilities compared to assets:
2005
Sepracor King
Current Assets 82.10% 42.08%
Fixed Assets 5.70% 10.20%
Investments 10.80% 0.62%
Intangible Assets 1.40% 32.62%
Other Assets 0.01% 2.60%
Current Liabilities 21.80% 32.76%
Total Liabilities 113% 33.45%
Total Equity -13% 66.55%
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King’s asset growth for 2005
2,965,242,000 - 2,924,156,000 = 1.41%
2,924,156,000
It appears that King’s business is fairly well established and cannot grow as much in one 
year as Sepracor managed to do with its 22.65 percent increase during 2005.  Yet this just 
means that the two are at different points in development.  King’s business is one that is 
more stable, likely making it less risky.  However, when looking at the working capital 
for the two companies, one observes that Sepracor had more of a cushion with its 
$768,639,000 difference in 2005 compared to King’s:
2005 2004
Current Assets 1,247,789,000 1,127,063,000 
Current 
Liabilities (971,460,000) (688,930,000)
Working Capital 276,329,000 438,133,000 
which was a change of
276,329,000 – 438,133,000 = -36.93%
438,133,000
Alternatively, Sepracor’s working capital increased nearly 21 percent.  Overall it appears 
that Sepracor is better managing its current assets and liabilities accounts.  However, 
with its negative shareholders’ equity, Sepracor likely does not measure up to King’s 
management of retained earnings.
For the past two years, King’s retained earnings activity has looked like this:
2005 2004
Retained Earnings, Beginning 637,120,000 797,408,000
Dividends 0 0
Net Income 117,833,000 (160,288,000)
Retained Earnings, Ending 754,953,000 637,120,000
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Compared to Sepracor’s million-plus-dollar deficit, King appears much more successful 
in this area.
King’s cash flow can be categorized in the following manner:
Cash Flow Activity 2005 2004
Operating 519,508,000 260,907,000
Investing -683,007,000 -154,071,000
Financing 857,000 4,580,000
Cash provided from operating activities of a 
discontinued operation 0 10,185,000
Cash provided from investing activities of a 
discontinued operation 0 27,927,000
Increase (Decrease) in Cash -162,642,000 149,528,000
For the year 2005, both Sepracor and King witnessed a significant decrease in overall 
cash.  Sepracor’s activities led to a $257,761,000 decrease, whereas King’s cash flow led 
to a $162,642,000 decrease.  King declined less, but neither company has a desirable 
appearance in this category.  However, it is important to note that King is not as heavily 
reliant upon financing activities as Sepracor is.  Operating activities provided a 
significant portion toward the overall cash-flow for King, meaning that the company is 
making money off of its products and not having to rely on borrowings to continue 
functioning.
While it is important to analyze the statements individually to understand the 
management of company assets, ratio analysis provides an easy way to compare 
companies side-by-side.
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Sepracor King
Accounts Receivable
Allowance for Doubtful Accounts 2.20% 5.21%
Days Sales in Accounts Receivable 66.61 days 48.15 Days
Accounts Receivable Turnover 7.35 times 8.38 Times
Inventory
Days Sales in Inventory 213.21 days 257.73 Days
Inventory Turnover Ratio 1.33 times 1.29 Times
Profitability Ratios
Profit Margin 0.65% 6.88%
Return on Assets 0.43% 3.96%
Return on Shareholders' Equity -2% 6.10%
Earnings Per Share $0.05 $0.48 
Liquidity Ratios
Current Ratio 3.77:1 1.28 :1
Quick Ratio 3.55:1 0.26 :1
Coverage Ratios
Debt-to-Total Assets 112.98% 33.45%
Times-Interest-Earned 1.22 times 16.09 Times
Book Value Per Common Stock Share ($1.59) $0.01
These ratios provide a lot of insight into the management strategies of both companies.   
The allowance for doubtful accounts percentage shows that King is more conservative in 
accounting for income as it reserves more than five percent for receivables it believes to 
be uncollectible, while Sepracor only has a little more than two percent allotted for the 
same cause.  Oddly enough, taking just 50.8 days versus 68.08, King appears to collect 
on its receivables more quickly than Sepracor.  Yet the accounts receivable turnover for 
the two does not vary by much.  King’s account was collected in full and reestablished 
7.84 times to Sepracor’s 7.18 times.
When it comes to inventory matters, Sepracor did somewhat better.  During the 
year, Sepracor’s manufactured products averaged sitting around 213.21 days before being 
sold, whereas King’s sat around 257.73 days.  This resulted in Sepracor’s having a 
slightly higher inventory turnover of 1.33 times over King’s 1.29 times.  Neither 
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company has anything to be proud of in this area.  Both need vast improvements on their 
ability to move products.
In profitability matters, King looks better.  For every dollar of sales at King, 6.88 
percent went to net income.  For Sepracor that number was only .65 percent.  King also 
better managed assets.  Each dollar invested in assets contributed to 3.96 percent of sales 
versus Sepracor’s .43 percent return.  When dealing with stockholders’ equity, for each
dollar invested by its shareholders, King was able to earn 6.1 percent of its net income.  
Sepracor’s losses in the past resulted in -2 percent return on stockholder investments.  
Thus, while each shareholder at King earned 48 cents for the year, Sepracor’s 
shareholders earned only a nickel.
However, Sepracor again takes the lead in liquidity.  For each dollar of current 
liability, Sepracor has it covered 3.77 times.  King only has a ratio of 1.28:1 of current 
assets-to-current liabilities, which is not much of a cushion at all.  When only the most 
liquid accounts are used to figure this matter, Sepracor’s ratio does not change much, 
going down to 3.55:1, but King’s drops to .26:1.  A company with a ratio of less than 1:1 
is seen as risky by lenders, which could potentially become a problem for King.
In the question of coverage, King is clearly the victor.  A 33.45 percent figure 
resulting from debt-to-total assets means that most of King’s assets were purchased using 
dollars from equity rather than borrowing.  Sepracor, however, has a score of 112.98 
percent, meaning it has heavily relied upon lenders’ money rather than investors’ money.  
Should lenders demand repayment, Sepracor might be in trouble, but King would likely 
be able to handle its small portion.  The times-interest-earned ratio shows that King could 
cover its debt obligations 16.09 times versus Sepracor’s 1.22 times.  Taking into 
30
consideration the amount of each company’s shareholders’ equity and the number of 
shares each were able to sell, King’s books indicate that one share is equal to 
approximately one cent.  However small this figure is, it is still better than Sepracor’s 
$(1.59) per share.
There is just one final comparison to perform, the results of the financial distress 
prediction.  Under Altman’s “Z-Score” Model, King received a score of
Z-Score
X1= 276,329,000/2,965,242,000 = 0.093 X 1.2 = 0.112
X2= 754,953,000/2,965,242,000 = 0.255 X 1.4 = 0.356
X3= (117,833,000+673,000+61,485,000+11,931,000)/2,965,242,000 = 0.065 X 3.3 = 0.214
X4= (16.92*241,802,724)/796,395,000 = 5.137 X .6 = 3.082
X5= 1,694,753,000/2,965,242,000 = 0.572 X 1.0 = 0.572
Z = 4.336
The score of 4.336 puts King in the “Safe” classification area.  Sepracor was far from that 
with its score of -0.366.  Using the Hopwood, McKeown, and Mutchler’s Logistic 
Regression Model, King’s likelihood of going bankrupt is
-0.8
X1= 117,833,000/2,965,242,000 = 0.040 X -32.36 = -1.286
X2= 1,247,789,000/1,694,753,000 = 0.736 X .55 = 0.405
X3= 1,247,789,000/971,460,000 = 1.284 X -.07 = -0.090
X4= 1,247,789,000/2,965,242,000 = 0.421 X 1.42 = 0.598
X5= 30,014,000/2,965,242,000 = 0.010 X -7.45 = -0.075
X6= 0/2,965,242,000 = 0.000 X 2.7 = 0.000
-1.249
Probability = 1 = 22.35%
(1 + 2.71 ^-(-1.249))
Compared to the 89.46 percent chance of bankruptcy that Sepracor scored, King’s 22.35 
percent looks much less risky.  Upon completion of this analysis it is apparent that at the 
end of 2005 King’s finances indicate that it is a better and safer investment than Sepracor.  
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While such an analysis may be a lengthy process, some form of it needs to be 
performed before an investment is made in any portfolio.  Many investors will look just 
to income figures, but investors must make sure to examine the notes contained within 
the report, as they are key to understanding some of the numbers and all of the 
accounting policies a company has adopted.  It is also important to keep in mind that 
these figures reflect a specified period of time and will be constantly updated.  What is a 
good investment one year will not necessarily be a good investment the following year;
thus, a reevaluation is needed for each new endeavor.
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